KereosKereos is developing a new class of targeted nanoparticles for a wide range of therapeutic indications. The nanoparticle platform incorporates an active pharmaceutical compound in the core of the particle and active homing molecules on the surface that are specific to disease-related expression of protein targets. This combination may provide more efficient delivery of the active pharmaceutical ingredient to the site of disease, while reducing or eliminating side effects. Kereos is currently focused on oncology drugs, the most advanced of which is a targeted formulation of paclitaxel that shows very promising results in pre-clinical models of cancer.